Jonathan Trent on Trabectedin for Soft Tissue Sarcoma
Jonathan Trent, MD, PhD, associate director for clinical research, director of the Sarcoma Medical Research Program at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, discusses the approval of trabectedin to treat patients with soft tissue sarcoma.Â
Jonathan Trent, MD, PhD, associate director for clinical research, director of the Sarcoma Medical Research Program at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, discusses the approval of trabectedin (Yondelis) to treat patients with soft tissue sarcoma.Â
The FDA approved trabectedin in October 2015 for patients with liposarcoma and leiomyosarcoma who were previously treated with chemotherapy that included an anthracycline.Â
The approval was based on a large, randomized study that found trabectedin was superior to dacarbazine chemotherapy in terms of response rates, duration of response, overall survival, and progression-free survival.Â
Oncology Nurses Provide Patients an Avenue to Supportive Care
August 2nd 2025Palliative care is often associated with a patient entering end of life treatment and giving up on their treatment, but that isn't the reality of what id can do for patients. And oncology nurses can help guide patients to the right supportive care for them.
Hyman B. Muss Discusses the Importance of Nurses in Treating Pregnant Women With Breast Cancer
August 2nd 2025Hyman B. Muss, MD, professor of medicine at the University of North Carolina School of Medicine, discusses the vital roles that nurses play when it comes to treating pregnant women with breast cancer.
